Recruiting
Phase 2

Sponsor:

Paul Szabolcs

Code:

NCT01962415

Conditions

Primary Immunodeficiency (PID)

Congenital Bone Marrow Failure Syndromes

Inherited Metabolic Disorders (IMD)

Hereditary Anemias

Inflammatory Conditions

Eligibility Criteria

Sex: All

Age: 2 - 55

Healthy Volunteers: Not accepted

Interventions

Hydroxyurea

Alemtuzumab

Fludarabine

Melphalan

Thiotepa

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Paul Szabolcs on 2025-03-18.